Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Population Health Research Institute · Hamilton Health Sciences · +32 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,987
total citations
- FWCI
- 217.21
- Percentile
- 100%
- References
- 34
Citations per year
Authors
1458- HCHertzel C. GersteinCorresponding
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- HMHelen M. Colhoun
University of Edinburgh
- GRGilles R. Dagenais
Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- RDRafael Díaz
Estudios Clínicos Latinoamérica
- MLMark Lakshmanan
Eli Lilly (United States)
Topics & keywords
Topics
Keywords
- Dulaglutide
- Medicine
- Type 2 diabetes
- Internal medicine
- Clinical endpoint
- Placebo
- Population
- Myocardial infarction
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.